BLOOD PRESSURE AMBULATORY MONITORING AS A METHOD FOR EARLY HYPERTENSION DIAGNOSTICS IN RHEUMATOID ARTHRITIS PATIENTS

Aim. To study the specifics of arterial hypertension (AH) taking the data from ambulatory monitoring (ABPM) in rheumatoid arthritis patients (RA).

Material and methods. Totally, 105 women with RA included (mean age — 55,49±7,02 y. o., mean age of RA onset — 45,17±10,87 y. o., mean duration of RA — 10,79±10,01 y., activeness by DAS28 — 5±1,14). By the data from office BP, 2 groups were selected: first group — 56 patients with RA and AH (RA+AH), second group — 49 patients with RA, non-AH. Exclusion criteria were smoking, diabetes, secondary AH, associated clinical conditions of AH, exacerbated chronic conditions, pregnancy, lactation, malignancies. Comparison group included 30 females with essencial AH, non-RA and other inflammatory disorders of the joints and spine (mean age — 55,9±6,2 y. o.), controls consisted of 22 almost healthy volunteers (females, mean age — 54,13±6,25 y. o.). Patients underwent ABPM, laboratory investigations with total cholesterol, creatinine, C-reactive protein (hsCRP), ESR. The glomerular filtration rate (GFR) was calculated by CKD-EPI, activeness of RA by DAS28.

Results. In general AH was found in 64,7% of RA patients, 11,4% were not aware of it, 57,3% did not control BP, and just 9,0% took 3-component antihypertension treatment. By ABPM, masked AH was found in 33,3% patients RA non-AH. Traditional risk factors in RA patients with essential and masked hypertension had same prevalence. By the ABPM data, RA hypertensives had worse nocturnal SBP profile comparing to AH and controls (p<0,05). More than a half of RA patients had high BP variability, in RA patients there was more prevalent BP raising at night (nightpeakers). The relation was found, of nocturnal SBP and HS-CRP (r=0,36, р<0,05), ESR (r=0,64, р<0,05).

Conclusion. AH in RA patients is more prevalent than in general population (53,3% by office BP, and 64,7% taking ABPM) The problem of AH screening in RA patients is important, and ABPM is recommended for earlier assessment.

1. Agca R, Heslinga SC, Rollefstad S, Heslinga M. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3.

2. Avina-Zubieta JA, Thomas J, Sadatsafavi M. et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–9.

3. Choy E, Ganeshalingam K, Semb AG et al. Cardiovascular Risk in Rheumatoid Arthritis: Recent Advances in the Understanding of the Pivotal Role of Inflammation, Risk Predictors and the Impact of Treatment. Rheumatology 2014;53(12):2143–2154.

4. Dougados M., Sourbier M, Antunez A et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann.Rheum. Dis. 2014;73:62-68.

5. Nikitina NM, Afanasyev IA, Romanova TA, Rebrov AP. Specific features of comorbidity in rheumatoid arthritis patients in different follow-up years. Sovremennaya revmatologiya 2015;1:39-43 DOI: 10.14412/1996-7012-2015-1-39-43. Russian (Никитина Н.М., Афанасьев И.А., Романова Т.А., Ребров А.П. Особенности коморбидности у больных ревматоидным артритом в разные годы наблюдения. Современная ревматология 2015;1:39-43).

6. Protogerou AD, Panagiotakos DB, Zampeli E et al. Arterial hypertension assessed “out-of-office” in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated “white coat” phenomenon. Arthritis Res Ther. 2013; 15(5): R142.

7. Monk HL, Muller S, Mallen CD et al. Cardiovascular screening in rheumatoid arthritis: a cross-sectional primary care database study. BMC Fam Pract. 2013 Oct 10;14:150. doi: 10.1186/1471-2296-14-150.

8. Recommendations for treatment of hypertension. ESH/ESC 2013. Russ J Cardiol 2014, 1 (105): 7-94. Russian (Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014; 1(105): 7-94).

9. Parati G, Stergion G, O`Brien E. et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-1366.

10. Chazova IE, Oshepkova EV, Zhernakova YuV. Clinical guidelines Diagnostics and treatment of arterial hypertension. Кardiologicheskij vestnik 2015;1:3-30. Russian (Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологический вестник 2015;1:3-30).

11. Filipovský J. White-coat hypertension and masked hypertension. Vnitr Lek. 2015;61(5):401-5.

12. Anthony J. Viera, Daichi Shimbo. Ambulatory blood pressure phenotypes and the risk for hypertension. Prevention of hypertension: public health. 2014;16:481.

13. Tientcheu D, Ayers C, Das SR et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015;66(20):2159-69. doi:10.1016/j.jacc.2015.09.007

14. Lyamina NP, Malinova LI, Nalivaeva AV et al. Masked hypertensionin in midlife working women. Kardiologiya 2016;3:30-34. Russian (Лямина Н.П., Малинова Л.И., Наливаева А.В. и др. Маскированная артериальная гипертензия у работающих женщин среднего возраста: аспекты скрининга и прогноза. Кардиология 2016;3:30-34). DOI: http://dx.doi.org/10.18565/cardio.2016.3.30-34

15. Peters MJ, van Halm VP, Voskuyl AE et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 2009; 61:1571–1579. doi: 10.1002/art.24836.

16. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303–1307.

17. Tyapkina MA, Voloshinova EV, Rebrov AP. Glomerular filtration rate as a marker of cardiovascular risk in patients with rheumatoid arthritis. Nefrologiya i dializ 2013;15(4): 339-340. Russian (Тяпкина М.А., Волошинова Е.В., Ребров А.П. Скорость клубочковой фильтрации как маркер сердечно-сосудистого риска у пациентов с ревматоидным артритом. Нефрология и диализ 2013;15(4): 339-340).

18. Kazuomi K. Morning surge and variability in blood pressure. A new therapeutic target? Hypertension 2005; 45, 485-6.

19. Nikitina NM, Romanova TA, Afanas'ev IA et al. Arterial hypertension in patients with rheumatoid arthritis. What you need to know for the diagnosis and consider the treatment? Racional'naya farmakoterapiya v kardiologii 2016; 12(5): 547-552. Russian (Никитина Н.М., Романова Т.А., Афанасьев И.А. и др. Артериальная гипертензия у больных ревматоидным артритом. Что нужно знать для диагностики и учитывать при лечении? Рациональная фармакотерапия в кардиологии 2016; 12(5): 547-552. DOI: 10.20996/1819-64-46-2016-12-5-547-552.

20. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ.2008; 336:1475–1482. doi: 10.1136/bmj.39609.449676.25